Oxford, United Kingdom

Rachel Alison Fallon

This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Amersham International Plc. Active years: 1999-2000.

USPTO Granted Patents = 2 

% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 18(Granted Patents)


Location History:

  • Littlemore, GB (1999)
  • Oxford, GB (2000)

Company Filing History:


Years Active: 1999-2000

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Rachel Alison Fallon: Innovator in Assay Systems

Introduction

Rachel Alison Fallon is a distinguished inventor based in Oxford, GB. She has made significant contributions to the field of assay systems, holding two patents that showcase her innovative spirit and technical expertise.

Latest Patents

Her latest patent relates to a reverse two-hybrid system employing post-translation signal modulation. This invention involves modified two-hybrid systems, particularly a reverse two-hybrid system that utilizes a reporter gene encoding a modifying agent, such as an enzyme. The system produces a detectable signal when there is an inhibition of binding of the two hybrid proteins, making it particularly useful for drug screening.

Career Highlights

Rachel is currently associated with Amersham International Plc, where she applies her knowledge and skills to advance research in her field. Her work has been instrumental in developing innovative solutions that enhance drug discovery processes.

Collaborations

Throughout her career, Rachel has collaborated with notable colleagues, including Douglas Hurd and Nicholas Ian Workman. These partnerships have contributed to her success and the advancement of her research.

Conclusion

Rachel Alison Fallon is a remarkable inventor whose work in assay systems has the potential to significantly impact drug screening methodologies. Her contributions continue to inspire innovation in the scientific community.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…